Cellectar Biosciences (CLRB) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lisata Therapeutics (LSTA) has outperformed Cellectar Biosciences (CLRB) over the past year, losing 52.6% versus a loss of 70.6%. Over five years, LSTA leads with a -93.6% price change compared with -99.5% for CLRB. Cellectar Biosciences is the larger company by market cap ($13.1 million vs $12.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | LSTA |
|---|---|---|
| Share price | $1.39 | $1.16 |
| Market cap | $13.14M | $12.48M |
| 1-day change | -7.95% | -1.28% |
| YTD return | -48.81% | -37.10% |
| 1-year return | -70.57% | -52.63% |
| 5-year return | -99.45% | -93.61% |
| EPS (TTM) | $-3.46 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $5.07 |
| 52-week low | $1.36 | $0.99 |
| Distance from 52-week high | -72.58% | -77.22% |
| Average volume | 61.52K | 291.91K |
| Shares outstanding | 9.45M | 10.80M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LSTA has outperformed CLRB by 17.9 percentage points over the past year.
CLRB vs LSTA FAQ
Which is bigger, Cellectar Biosciences or Lisata Therapeutics?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $13.14M compared with $12.48M for Lisata Therapeutics (LSTA).
Which stock has performed better over the past year, CLRB or LSTA?
LSTA returned -52.63% over the past 12 months, compared with -70.57% for CLRB (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Lisata Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.